Kiromic BioPharma Management

Management criteria checks 1/4

Kiromic BioPharma's CEO is Pietro Bersani, appointed in Jan 2022, has a tenure of 2.25 years. total yearly compensation is $906.79K, comprised of 68% salary and 32% bonuses, including company stock and options. directly owns 6.74% of the company’s shares, worth $267.58K. The average tenure of the management team and the board of directors is 2 years and 3 years respectively.

Key information

Pietro Bersani

Chief executive officer

US$906.8k

Total compensation

CEO salary percentage	68.0%
CEO tenure	2.3yrs
CEO ownership	6.7%
Management average tenure	2yrs
Board average tenure	3yrs

Recent management updates

Recent updates

Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year

Oct 06

CEO Compensation Analysis

How has Pietro Bersani's remuneration changed compared to Kiromic BioPharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$907k	US$617k	-US$23m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$808k	US$497k	-US$35m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$33m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$336k	US$168k	-US$26m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$63k	n/a	-US$20m

Compensation vs Market: Pietro's total compensation ($USD906.79K) is above average for companies of similar size in the US market ($USD670.12K).

Compensation vs Earnings: Pietro's compensation has increased whilst the company is unprofitable.

CEO

Pietro Bersani (55 yo)

2.3yrs

Tenure

US$906,788

Compensation

Mr. Pietro Bersani, CPA, J.D., serves as Chief Executive Officer at Kiromic BioPharma, Inc. since May 10, 2022 and serves as Director since January 27, 2022. He served as Principal Financial Officer at Kir...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Pietro Bersani	CEO & Director	2.3yrs	US$906.79k	6.74% $ 267.6k
Brian Hungerford	Chief Financial Officer	less than a year	US$165.73k	no data
Leonardo Mirandola	Chief Scientific Officer & Interim COO	1.8yrs	US$383.32k	0.0081% $ 323.4
Scott Dahlbeck	Chief of Staff	4.5yrs	US$359.08k	1.11% $ 44.1k

2.0yrs

Average Tenure

51yo

Average Age

Experienced Management: KRBP's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Pietro Bersani	CEO & Director	3.8yrs	US$906.79k	6.74% $ 267.6k
Michael Nagel	Independent Chairperson of the Board	3.5yrs	US$97.89k	1.89% $ 74.8k
Pamela Misajon	Independent Director	less than a year	US$27.23k	0.58% $ 23.1k
Ruggero De Maria	Member of Scientific Advisory Board	no data	no data	no data
Amorette Barber	Member of Scientific Advisory Board	no data	no data	no data
Martin D'Souza	Member of Scientific Advisory Board	no data	no data	no data
Sandeep Dhanda	Member of Scientific Advisory Board	no data	no data	no data
Luca Gattinoni	Member of Scientific Advisory Board	3.3yrs	no data	no data
Franco Locatelli	Member of Scientific Advisory Board	2.7yrs	no data	no data
Michael Catlin	Independent Director	less than a year	US$30.23k	0.58% $ 23.1k

3.0yrs

Average Tenure

62yo

Average Age

Experienced Board: KRBP's board of directors are not considered experienced ( 3 years average tenure), which suggests a new board.

Kiromic BioPharma Management

Management criteria checks 1/4

Key information

Recent management updates

Less than half of directors are independent

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Recent updates

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Nasdaq to Delist the Securities of Kiromic BioPharma

Kiromic Biopharma, Inc. Announces Deltacel™? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center

Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14, 2023, Suspended from Trading on Nasdaq Capital Market

Less than half of directors are independent

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Kiromic BioPharma Receives Non-Compliance Notice from Nasdaq

Frank Tirelli Resigns His Position as Director and Member of the Audit Committee, and the Nominating and Corporate Governance Committee of Kiromic Biopharma, Inc

High number of new and inexperienced directors

Kiromic BioPharma, Inc. announced that it has received $2 million in funding

Kiromic Biopharma Announces FDA Feedback from Type B Pre-Ind Meeting Confirms Deltacel Development Strategy

Kiromic Biopharma surges 43% as company to begin lung cancer therapy trial in Q1 next year

Gainey Mckenna & Egleston Files the First Class Action Lawsuit Against Kiromic Biopharma, Inc

Nasdaq Grants Extension to Kiromic BioPharma to Regain Compliance

The Klein Law Firm Announces Class Action Complaint Against Kiromic Biopharma, Inc

Gainey McKenna & Egleston Files Class Action Lawsuit Against Kiromic BioPharma, Inc

Kiromic BioPharma, Inc. Appoints Leonardo Mirandola as Chief Scientific Officer

Dr. Leonardo Mirandola is the new Chief Scientific Officer of Kiromic biopharma

High number of new and inexperienced directors

Kiromic BioPharma, Inc. Appoints Pietro Bersani to the Role of Chief Executive Officer, Effective May 10, 2022

Kiromic BioPharma, Inc. Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Kiromic BioPharma, Inc., Annual General Meeting, Jun 22, 2022

Kiromic BioPharma, Inc. announced delayed annual 10-K filing

Kiromic BioPharma, Inc. Announces Board Appointments

High number of new and inexperienced directors

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

High number of new and inexperienced directors

Kiromic BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Kiromic expands in-house cell therapy manufacturing facility, names new COO

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy

Kiromic Biopharma, Inc. Announces Identification of Novel Targets for Allogeneic Car Gamma Delta T-Cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic BioPharma, Inc. Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy

Kiromic Biopharma, Inc. to Resubmit Two Expanded INDs to the FDA for its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors

New 90-day high: US$11.81

Kiromic Biopharma, Inc. Enters into A Strategic Alliance Agreement with Leon Office (H.K.) Ltd

New 90-day high: US$10.45

Kiromic Announces License Agreement With Longwood University for chPD1

Kiromic BioPharma, Inc. Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

Kiromic BioPharma, Inc. Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA

Kiromic BioPharma files two IND applications for CAR-T therapy in cancer

Kiromic BioPharma reports Q3 results

Kiromic BioPharma, Inc. Announces Management Changes

Kiromic BioPharma, Inc. has completed an IPO in the amount of $15 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age